<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>386</serviceExecutionTime><Drug id="60297"><DrugName>valproic acid analog (epilepsy/bipolar disorder), Jazz Pharmaceuticals</DrugName><DrugSynonyms><Name><Value>KEY-12</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>valproic acid analog (epilepsy/bipolar disorder), Jazz Pharmaceuticals</Value></Name><Name><Value>propylisopropyl acetamide</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1007377">Jazz Pharmaceuticals plc</CompanyOriginator><CompaniesSecondary><Company id="1007377">Jazz Pharmaceuticals plc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1007377" type="Company"><TargetEntity id="4297329846" type="organizationId">Jazz Pharmaceuticals PLC</TargetEntity></SourceEntity><SourceEntity id="119" type="ciIndication"><TargetEntity id="G40" type="ICD10"></TargetEntity><TargetEntity id="345" type="ICD9"></TargetEntity><TargetEntity id="10015037" type="MEDDRA"></TargetEntity><TargetEntity id="D004827" type="MeSH"></TargetEntity><TargetEntity id="-2005570698" type="omicsDisease"></TargetEntity><TargetEntity id="115" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="653" type="ciIndication"><TargetEntity id="F31" type="ICD10"></TargetEntity><TargetEntity id="296" type="ICD9"></TargetEntity><TargetEntity id="10057667" type="MEDDRA"></TargetEntity><TargetEntity id="D001714" type="MeSH"></TargetEntity><TargetEntity id="-1667300745" type="omicsDisease"></TargetEntity><TargetEntity id="47" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="179" type="Action"><TargetEntity id="428" type="Mechanism">GABA Aminotransferase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="7841" type="Action"><TargetEntity id="1749" type="Mechanism">Histone Deacetylase 1 (HDAC1) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00783" type="ciTarget"><TargetEntity id="289439143183" type="siTarget">4-aminobutyrate aminotransferase, mitochondrial</TargetEntity><TargetEntity id="-729498017" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-00923" type="ciTarget"><TargetEntity id="205759791330653" type="siTarget">Histone deacetylase 1</TargetEntity><TargetEntity id="-1584981221" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="119">Epilepsy</Indication><Indication id="653">Bipolar disorder</Indication></IndicationsSecondary><ActionsPrimary><Action id="179">GABA transaminase inhibitor</Action><Action id="7841">Histone deacetylase-1 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2941">Antidepressant</Action><Action id="70">Anticonvulsant agent</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N3</Code><Name>ANTI-EPILEPTICS</Name></Ephmra><Ephmra><Code>N6A</Code><Name>ANTI-DEPRESSANTS AND MOOD STABILISERS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-30T06:12:13.000Z</LastModificationDate><ChangeDateLast>2011-02-14T11:04:29.000Z</ChangeDateLast><AddedDate>2008-05-23T17:03:23.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1007377" linkType="Company"&gt;Jazz Pharmaceuticals&lt;/ulink&gt; was investigating KEY-12 (propylisopropyl acetamide (PID), a structural analog of &lt;ulink linkID="5265" linkType="Drug"&gt;valproic acid&lt;/ulink&gt;, for the potential treatment of epilepsy and bipolar disorder.  By March 2008,  animal studies to evaluate hepatotoxicity and teratogenicity were ongoing [&lt;ulink linkID="909706" linkType="Reference"&gt;909706&lt;/ulink&gt;], [&lt;ulink linkID="885702" linkType="Reference"&gt;885702&lt;/ulink&gt;]. However, in 2009,  the company returned the rights on the compound to &lt;ulink linkID="20978" linkType="Company"&gt;Yissum&lt;/ulink&gt; due to financial reasons, and so KEY-12 would not be developed further [&lt;ulink linkID="1096837" linkType="Reference"&gt;1096837&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In June 2008, preclinical data were presented at the Ninth Eilat Conference on New Anti-Epileptic Drugs in Sitges, Spain. Racemic PID and its individual enantiomers were several times more potent than valproic acid in a variety of seizure models, and in the Chung model of neuropathic pain. Some differences in potency in seizure models, and in animal pharmacokinetics, have been found between the two enantiomers. (R)-PID and (S)-PID and their corresponding acids had no teratogenic effect in a mouse model sensitive to valproic acid-induced teratogenicity [&lt;ulink linkID="920367" linkType="Reference"&gt;920367&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1007377">Jazz Pharmaceuticals plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="653">Bipolar disorder</Indication><StatusDate>2009-12-31T00:00:00.000Z</StatusDate><Source id="1096837" type="CONFERENCE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1007377">Jazz Pharmaceuticals plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="119">Epilepsy</Indication><StatusDate>2009-12-31T00:00:00.000Z</StatusDate><Source id="1096837" type="CONFERENCE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1007377">Jazz Pharmaceuticals plc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate>2008-03-13T00:00:00.000Z</StatusDate><Source id="909706" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1007377">Jazz Pharmaceuticals plc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate>2008-03-13T00:00:00.000Z</StatusDate><Source id="909706" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00783"><Name>GABA transaminase</Name><SwissprotNumbers><Swissprot>O13837</Swissprot><Swissprot>P14010</Swissprot><Swissprot>P17649</Swissprot><Swissprot>P22256</Swissprot><Swissprot>P40829</Swissprot><Swissprot>P49604</Swissprot><Swissprot>P50457</Swissprot><Swissprot>P50554</Swissprot><Swissprot>P61922</Swissprot><Swissprot>P63505</Swissprot><Swissprot>P80147</Swissprot><Swissprot>P80404</Swissprot><Swissprot>P94427</Swissprot><Swissprot>Q21217</Swissprot><Swissprot>Q9BGI0</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00923"><Name>Histone deacetylase-1</Name><SwissprotNumbers><Swissprot>O09106</Swissprot><Swissprot>O42227</Swissprot><Swissprot>P56517</Swissprot><Swissprot>P56518</Swissprot><Swissprot>Q13547</Swissprot><Swissprot>Q91695</Swissprot><Swissprot>Q94517</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>2 references added [&lt;ulink url="utility.reference?i_reference_id=1096837" linkType="reference" linkID="1096837"&gt;1096837&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=1096715" linkType="reference" linkID="1096715"&gt;1096715&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>